By vgreene, 16 April, 2020 The QT Interval in Patients With COVID 19 Treated With Hydroxychloroquine and Azithromycin
By vgreene, 16 April, 2020 Study considerations: non-comparative; small sample size; pts had other risk factors for QT prolongation besides HCQ plus AZ tx; HCQ and AZ dosing not provided
By vgreene, 16 April, 2020 Mean QTc interval increased from 435 msec at baseline to 463 msec; 30% pts had QTc prolonged by >40 msec; 11% pts developed QTc interval of >500 msec; no cases of torsade de pointes; acute renal failure only predictor of maximal QTc >500 msec on multivari
By vgreene, 16 April, 2020 Retrospective, observational study; 84 hospitalized pts (mean age, 63y) w/ confirmed SARS-CoV-2 treated w/ HCQ plus AZ; comorbidities incl CAD (11%), HTN (65%), CKD (7%), DM (20%), COPD (8%), CHF (2%); 7% on amiodarone tx
By vgreene, 16 April, 2020 Hydroxychloroquine in Patients With COVID-19: An Open-label Randomized, Controlled Trial
By vgreene, 16 April, 2020 Study considerations: not peer reviewed; randomized but open-label; most pts received other potential antivirals; delayed tx initiation from sx onset; almost all pts had mild-moderate dz; higher HCQ dose and duration than other studies
By vgreene, 16 April, 2020 No difference in primary endpoint of viral clearance (85% HCQ vs 81% SOC) or secondary endpoint of sx improvement rate (67% HCQ vs 60% SOC); higher rate of ADRs in HCQ group (30% vs 9%)
By vgreene, 16 April, 2020 Multicenter, open-label, RCT; 150 hospitalized pts (mean age, 46y, 99% mild or moderate dz, 76% received other antivirals) randomized 1:1 to SOC, or SOC plus HCQ 1,200 daily x3 days, then 800 mg daily for total of 2-3wk based on dz severity; 17 days mean